.png)
German (DE) 
English (US) 
Spanish (ES) 
French (FR) 
Hindi (IN) 
Italian (IT) 
Russian (RU) Abdul Rahman
Tue, Jun 17, 2025, 1:24 AM 1 min read
In This Article:
Baxter International Inc. (NYSE:BAX) is one of the 12 best healthcare stocks to buy now. On June 11, UBS reiterated a ‘Neutral’ rating on the stock and a $35 price target. The Neutral stance follows a meeting with the company’s Head of Investor Relations.
everything possible/Shutterstock.com
According to UBS, the company has demonstrated momentum across its portfolio with products like Novum IQ and Progressa+. Consequently, the products position the company to maintain the mid to single-digit sales growth achieved in recent quarters. Over the last 12 months, the company’s revenue has grown by 15.4%, reaching $10.8 billion.
Nevertheless, UBS remains cautious amid growing uncertainty about Baxter International’s new CEO. Additionally, there is uncertainty over the direction in which the company’s post-Vantive sales strategy will take in both organic and inorganic investments. UBS has warned that the strategic uncertainties could affect the company’s market growth rates, making it difficult to predict sales and earnings upside.
Baxter International Inc. (NYSE:BAX) is a global medical technology company that develops, manufactures, and markets a wide range of healthcare products and technologies. It focuses on products related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
While we acknowledge the potential of BAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10.
Disclosure: None.
Comments